ABL Bio reports Q1 2026 revenue of KRW 13.1B; major licensing deals with GSK and Lilly drive growth outlook

Q1 2026 consolidated revenue of KRW 13.14B (up from KRW 2.16B YoY), operating loss of KRW 17.22B, net loss of KRW 14.66B.
Major licensing deals with GSK (up to GBP 2.14B, KRW 38.5B upfront) and Lilly (up to USD 2.6B, KRW 40B upfront) enhance future revenue prospects.
Cash and cash equivalents of KRW 186.7B, net debt of -KRW 74B (net cash), indicating strong financial position.
ABL001 (bile duct cancer) granted US Orphan Drug and Fast Track designations; Compass Therapeutics advancing phase 2/3.
R&D expenses of KRW 22.05B (167.9% of revenue), reflecting continued aggressive investment.
Total equity of KRW 183.3B, debt-to-equity ratio of 62.6%, maintaining healthy financial soundness.
Borrowings of KRW 55B (short-term) with collateral of KRW 51.6B, stable debt structure.